Table 2.
Correlation of MPO concentration and activity in the CSF with demographic and clinical parameters in the cohort of patients with idiopathic Parkinson’s disease.
| MPO Content | MPO Activity | |||
|---|---|---|---|---|
| Parameter | Correlation, r | p | Correlation, r | p |
| Age, years | 0.298 | NS | −0.022 | NS |
| Body mass index | 0.102 | NS | −0.021 | NS |
| Education, years | 0.091 | NS | 0.076 | NS |
| Albumin index | 0.024 | NS | −0.129 | NS |
| Leukocyte count, cells/µL | 0.123 | NS | 0.202 | NS |
| Serum MPO concentration (pg/mL) | −0.091 | NS | −0.079 | NS |
| Serum MPO activity (mU/mL) | −0.121 | NS | 0.385 | NS |
| CSF MPO activity | 0.471 | 0.0049 | ||
| Levodopa equivalent daily dose, mg | 0.037 | NS | 0.244 | NS |
| Disease duration, years | 0.475 | 0.0045 | 0.070 | NS |
| Age-at-PD onset, years | −0.156 | NS | 0.034 | NS |
| Hoehn–Yahr stage | −0.121 | NS | 0.128 | NS |
| Modified Schwab–England | −0.175 | NS | 0.028 | NS |
| MDS-UPDRS part III (on) | −0.059 | NS | 0.045 | NS |
| Total MDS-UPDRS (I-III) (on) | 0.010 | NS | −0.096 | NS |
| MDS-UPDRS part IV (all patients) | 0.044 | NS | 0.093 | NS |
Statistical correlation was carried out with the Pearson’s test. Correlation value was adjusted for age, age-a-PD onset, body mass index, and education. Abbrev.: CSF, cerebrospinal fluid; MPO, myeloperoxidase; NS, no significant; MDS-UPDRS, International Parkinson and Movement Disorder Society-Sponsored revision of the Unified Parkinson’s Disease Rating Scale; PD, Parkinson’s disease; p, two-tailed probability value.